Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TTI vs HHS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HHS Captures Overall Composite Edge (61.8 BUY vs 35.2 SELL), While TTI Leads 4–1 on Growth & Valuation Pillars

HHS Overall Winner 6-Pillar Tally: TTI 4 – 1 HHS (1 Tie) Matrix Metrics: TTI 5 – 5 HHS

As of Nov 16, 2026, Harte Hanks, Inc. (HHS) captures the overall head-to-head institutional edge over TETRA Technologies, Inc. (TTI) on higher Unified Composite conviction (61.8/100 BUY vs. 35.2/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples), while TTI wins 4–1 across the 6-pillar growth and valuation breakdown. TTI trades at $6.20 (21.3x Forward P/E, 7.4% operating margin) versus HHS at $3.85 (14.3x Forward P/E, -3.2% operating margin).

  • Growth vs. Quality Trade-Off: HHS earns the overall head-to-head edge with a stronger Unified Composite Score (61.8/100 BUY vs. TTI 35.2/100 SELL) and 0.49β · 46% Vol risk profile, whereas TTI leads top-line expansion (+9.6% YoY revenue growth, 1.82x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TTI vs HHS
TTI NYSE
TETRA Technologies, Inc.
Crude Petroleum & Natural Gas
$6.20
-2.97% 1D
Market Cap $945.5M
TTM Revenue $657M
Forward P/E 21.3x
Beta / 30D Vol 1.45β · 61% Vol
Unified Composite Score
35.2 / 100 SELL
Tech 8.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 55
RSI-14: 55.5 · SMA20: $5.85 · SMA50: $5.99
HHS US Equity Head-to-Head Winner
Harte Hanks, Inc.
Services-Direct Mail Advertising Services
$3.85
-3.99% 1D
Market Cap $30.0M
TTM Revenue $155M
Forward P/E 14.3x
Beta / 30D Vol 0.49β · 46% Vol
Unified Composite Score
61.8 / 100 BUY
Tech 76.0 Fund 61.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 38.2 · SMA20: $3.95 · SMA50: $4.26

6-Pillar Scorecard Institutional Category Breakdown (TTI 4 – 1 HHS)

Columns: Metric · TTI · HHS
1. Valuation Multiples HHS
Forward P/E 21.3x 14.3x
Trailing P/E 91.0x 14.3x
PEG Ratio 1.82x 1.19x
EV / Revenue 1.4x 0.3x
2. Growth & Scale TTI
Revenue Growth (YoY) +9.6% -1.7%
Earnings Growth (YoY) +54.0% -90.3%
TTM Revenue (USD) $657M $155M
Market Cap $945.5M $30.0M
3. Profitability & Quality TTI
Gross Margin 28.8% 16.1%
Operating Margin 7.4% -3.2%
Net Profit Margin 1.4% -3.7%
Return on Equity (ROE) 2.9% -30.4%
4. Balance Sheet & Cash Flow TTI
Cash Generation (TTM) $87M EBITDA -$4.5M
Cash Flow Margin 13.2% EBITDA Mgn -2.9%
Net Cash / Leverage $2.80 Book/Sh · 2.9% ROE $17M Net Debt (1.10x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 57.2% (<1st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat TTI
OpEx & R&D Intensity 21.4% of Rev ($140M) 19.3% of Rev ($30M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Oil & Gas Equipment & Services Operator Conglomerates Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TTI (5) vs HHS (5)
Institutional Metric TTI HHS Criterion Row Edge
Market Capitalization
Scale
$945.5M $30.0M Larger Scale TTI
Trailing P/E Ratio
Valuation
91.0x 14.3x Lower Multiple HHS
Forward P/E Ratio
Valuation
21.3x 14.3x Lower Multiple HHS
Revenue Growth (YoY)
Growth
+9.6% -1.7% Higher Growth TTI
Operating Margin (TTM)
Profitability
7.4% -3.2% Higher Margin TTI
Net Profit Margin
Profitability
1.4% -3.7% Higher Margin TTI
Return on Equity (ROE)
Capital Efficiency
2.9% -30.4% Higher ROE TTI
52-Week Range Position
Momentum
17% ($5–$13) 69% ($2–$5) Stronger Trend HHS
Beta / 30D Volatility
Risk Regime
1.45β · 61% Vol 0.49β · 46% Vol Lower Realized Risk HHS
Unified Institutional Score
Composite Signal
35.2 / 100 (SELL) 61.8 / 100 (BUY) Higher Composite HHS
Trailing 12M Revenue (USD)
Operating Scale
$657M $155M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
28.8% 16.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.82x PEG · 1.4x EV/Rev 1.19x PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$87M EBITDA ($2.80 Book/Sh · 2.9% ROE) -$4.5M ($17M Net Debt (1.10x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TTI +26.8 pp
TTI: +16.54% · HHS: -10.26%
3M Horizon HHS +18.8 pp
TTI: -22.31% · HHS: -3.51%
6M Horizon HHS +73.13 pp
TTI: -36.61% · HHS: +36.52%
1Y Horizon HHS +52.53 pp
TTI: -17.44% · HHS: +35.09%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TTI vs HHS. Trailing 12-month operating profitability (TTI 7.4% vs HHS -3.2%) and valuation multiples (TTI 21.3x vs HHS 14.3x Forward P/E) are benchmarked directly in Pillar 4 below.

TTI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$657M
Gross Margin28.8%
Op. Margin7.4%
ROE / Fwd P/E2.9% · 21.3x
HHS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$155M
Gross Margin16.1%
Op. Margin-3.2%
ROE / Fwd P/E-30.4% · 14.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TTI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 57.2%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TTI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HHS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HHS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TTI Moat Profile Cyclical / Execution-Driven Positioning
Oil & Gas Equipment & Services Operator
Competes within the Oil & Gas Equipment & Services value chain with $945.5M market capitalization and 7.4% operating margin.
OpEx & R&D Reinvestment 21.4% of Rev ($140M)
90D Engineering Disclosures 0 Published
HHS Moat Profile Cyclical / Execution-Driven Positioning
Conglomerates Operator
Competes within the Conglomerates value chain with $30.0M market capitalization and -3.2% operating margin.
OpEx & R&D Reinvestment 19.3% of Rev ($30M)
90D Engineering Disclosures 0 Published

Investor FAQ TTI vs HHS Key Questions & Quantitative Answers

As of Nov 16, 2026, Harte Hanks, Inc. (HHS) captures the overall head-to-head institutional edge over TETRA Technologies, Inc. (TTI) on higher Unified Composite conviction (61.8/100 BUY vs. 35.2/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples), while TTI wins 4–1 across the 6-pillar growth and valuation breakdown. TTI trades at $6.20 (21.3x Forward P/E, 7.4% operating margin) versus HHS at $3.85 (14.3x Forward P/E, -3.2% operating margin). Growth vs. Quality Trade-Off: HHS earns the overall head-to-head edge with a stronger Unified Composite Score (61.8/100 BUY vs. TTI 35.2/100 SELL) and 0.49β · 46% Vol risk profile, whereas TTI leads top-line expansion (+9.6% YoY revenue growth, 1.82x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

TTI leads the Growth & Scale pillar: TTI posts +9.6% YoY revenue growth and +54.0% YoY earnings growth on $657M TTM revenue (28.8% gross margin, 7.4% operating margin), compared with HHS at -1.7% YoY revenue growth and -90.3% YoY earnings growth on $155M TTM revenue (16.1% gross margin, -3.2% operating margin). On trailing 12-month operating scale, TTI generates $657M in USD-normalized revenue versus $155M for HHS. In operating R&D and SG&A reinvestment, TTI deploys 21.4% of Rev ($140M) (0 90-day corporate R&D disclosures) versus 19.3% of Rev ($30M) (0 disclosures) for HHS.

HHS screens cheaper on headline valuation multiples. TTI trades at 21.3x Forward P/E, 91.0x Trailing P/E, 1.82x PEG, and 1.4x EV/Revenue (13.2% EBITDA margin), whereas HHS trades at 14.3x Forward P/E, 14.3x Trailing P/E, 1.19x PEG, and 0.3x EV/Revenue (-2.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TTI (2.9% ROE) versus HHS (-30.4% ROE) capital efficiency.

In options market volatility and institutional positioning, TTI carries 57.2% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.45β · 61% Vol realized risk). By comparison, HHS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.49β · 46% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.